Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
Aim of this prospective randomized trial is to compare maintenance treatment with
panobinostat interspersed with donor lymphocyte infusions (DLI) versus the standard approach
of pre-emptive DLI alone in patients with poor-risk AML/MDS having favorably received an
allogeneic HSCT followed by engraftment, donor chimerism and hematopoietic reconstitution.
Phase:
Phase 3
Details
Lead Sponsor:
Goethe University
Collaborators:
Jan J. Cornelissen (HOVON-SAKK) Sebastian Giebel (PALG)